Fact.MR – A Market Research and Competitive Intelligence Provider: The global heparin API market is projected to demonstrate healthy growth over the forecast period, from 2021 to 2031, as per a research study by Fact.MR.
Heparin API Demand will Soar Amidst Increasing Cases of Blood Disorders
The recent market research study conducted by Fact.MR offers heparin API market demand outlook in term of key segments, including product type, active, drug type, and indication. The survey report also reveals information on growth drivers, trends, and opportunities affecting the growth trajectory of the heparin API market
Fact.MR – A Market Research and Competitive Intelligence Provider: The global heparin API market is projected to demonstrate healthy growth over the forecast period, from 2021 to 2031, as per a research study by Fact.MR. Implementation of regulatory compliances, encouraging the production of heparin API to eliminate contaminants from pharmaceutical grade products, is favoring the growth of the market.
The rise in incidence of cardiovascular disorders, venous thromboembolism, and coronary heart diseases will create a conducive environment for heparin API sales. According to a report published by the American Heart Association, approximately 92.1 million adults were diagnosed with cardiovascular diseases in the U.S. in 2018. The report also states that 1 in every 3 deaths is caused by the disease, accounting for nearly 2,300 deaths per day.
Heparin API is the most commonly used anticoagulant in several medical procedures. It plays a crucial role in the treatment and prevention of blood clots during surgical and medical procedures such as kidney dialysis.
Thanks to the increase in number of heparin manufacturers and rise in investments towards research and development (R&D) activities, the market for heparin API is poised to expand at a high pace. North America is forecast to lead the global heparin API market due to the increasing prevalence of cardiovascular diseases and coronary heart ailments in countries such as the U.S. and Canada.
“Due to the higher presence of contaminants and impurities in animal-sourced heparin, manufacturers are shifting their focus the production of bovine-sourced heparin. This is expected to drive the demand for heparin API in the assessment period,” says a Fact.MR analyst.
For More Information On How To Improve Your Heparin API Market Footprint, Request A Sample Here
https://www.factmr.com/connectus/sample?flag=S&rep_id=5190
Key Takeaways from Heparin API Market Study
- The U.S is anticipated to lead in the heparin API market in North America, owing to the presence of a highly developed healthcare infrastructure.
- In Asia Pacific, China is forecast to contribute maximum revenue share, due to the increasing number of cardiovascular disorders in the country.
- Favored by the growing investments towards research and development activities, the market in the U.K. is projected to account for the largest share in Europe.
- India is expected to emerge as a highly remunerative market in the forecast period supported by constantly improving healthcare infrastructure and the rising number of domestic players in the country.
- Based on the indication, the acute coronary syndrome is likely to account for the largest share in the segment.
Key Drivers
- Rising incidence of blood-related disorders and cardiovascular diseases will propel the demand for the heparin API.
- Increasing number of surgical procedures conducted across the globe due to various medical conditions is expected to drive the market.
- Growing number of heparin manufacturers in Asia-Pacific is creating prospects for expansion.
Key Restraints
- Adverse effects associated with the heparin API are hampering the sales.
- Stringent pricing regulation imposed by the government is posing a challenge for the growth of the heparin API market.
Ask Your Heparin API Market Related Questions & Get Customized Reports https://www.factmr.com/connectus/sample?flag=RC&rep_id=5190
Competitive Landscape
Leading companies operating the heparin API market are emphasizing on introducing new products to expand their product portfolio and increase market revenue share. Besides this, some of the players are adopting inorganic strategies such as acquisition, merger, strategic collaboration, and agreement to maintain their lead in the market. For instance,
- In September 2019, Hikma Pharmaceuticals, a British multinational pharmaceutical company, announced launching prefilled heparin sodium injection in the U.S. for prophylaxis and treatment of diseases such as venous thrombosis and pulmonary embolism.
- In 2018, Fresenius Kabi, global healthcare company headquartered in Germany announced introducing its novel ready-to-administer non DEHP freeflex bags heparin sodium to expand the Fresenius Kabi’s critical care product portfolio.
Some of the prominent heparin API providers profiled by Fact.MR are:
- Pfizer Inc.
- Aspen Oss BV
- Shenzhen Hepalink Pharmaceutical Co. Ltd.
- Jiulong Biochemicals
- Bioiberica S.A.
- Changzhou Qianhong
- Sichuan Deebio Pharmaceutical Co. Ltd.
- Yino Pharma Limited
- Tiandong County
- Opocrin Spa
- Hebei Changshan Biochemical Pharmaceutical Co. Ltd.
- Yantai Dongcheng
More Valuable Insights on Heparin API Market
Fact.MR, in its new report, offers an unbiased analysis of the global heparin API market, analyzing forecast statistics through 2021 and beyond. The survey reveals growth projections on in the heparin API market with detailed segmentation:
By Product type:
- Generic
- Innovative
By Active:
- Heparin Sodium
- Heparin Calcium
- Others
By Drug type:
- Over-the-counter
- Prescribed
By Indication:
- Acute Coronary Syndrome
- Atrial Fibrillation
- Hemofiltration
- Deep-Vein Thrombosis
- Cardiopulmonary Bypass
- Infix Central/Peripheral Venous Catheters
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Key Questions Covered in the Heparin API Market Report
- The report offers insight into heparin API demand outlook for 2021-2031
- The market survey also highlights projected sales growth for the heparin API market between 2021 and 2031
- Heparin API market analysis identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Heparin API market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, collaborations or partnerships, and others.
Explore Fact.MR’s Coverage on the Healthcare Domain
Anticoagulants Market - During the forecast period, demand for advanced anticoagulants is likely to be hampered. Furthermore, these drugs are used for long-term treatment, which necessitates individuals allocating an additional budget for these advanced drugs for an extended period of time. As a tool to increase anticoagulant exposure, players in the anticoagulants market are stepping forward to shoulder the financial burden of individuals through patient-assistance programs.
Cardiopulmonary Stress Testing Systems Market - The cardiopulmonary exercise testing systems (CPET) segment is expected to dominate the global cardiopulmonary stress testing systems market. This is due to an increase in the demand for novel testing systems among critically ill COVID-19 patients. The CPET segment is expected to account for more than half of the global cardiopulmonary stress testing services market, growing at a rate of 1.3x during the forecast period. North America is on track to account for one-third of the global cardiopulmonary stress testing market.
Atrial Fibrillation (AF) Ablation Market - Over the forecast period, the global market for atrial fibrillation is expected to grow rapidly. With the advancement of technology, the majority of devices are introduced into the market, creating competition among local and regional players. With the rise in cardiac diseases, the market for atrial fibrillation ablation is expected to grow. The geriatric population is expected to be the most affected.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR